8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure
Key Takeaways
Preconception care aims to identify and modify biomedical, behavioral, and social risks to maternal and fetal health before conception occurs, intervening prior to the critical organogenesis window (gestational weeks 3 through 8 post-conception / menstrual weeks 5 through 10).
Pregestational diabetes mandates strict glycemic control aiming for an A1C <6.5% prior to conception to minimize congenital cardiac anomalies, neural tube defects, and caudal regression syndrome, together with preconception folic acid.
Chronic hypertension requires transitioning off fetotoxic renin-angiotensin-aldosterone system (RAAS) inhibitors (ACE inhibitors, ARBs) and mineralocorticoid receptor antagonists to pregnancy-safe first-line agents: labetalol, extended-release nifedipine, or methyldopa.
Folic acid prevents neural tube defects: the USPSTF recommends 0.4–0.8 mg daily starting at least 1 month before conception, and after a prior NTD-affected pregnancy ACOG and CDC recommend 4 mg daily from at least 1 month before conception through the first trimester.
Live attenuated vaccines (MMR, varicella) are strictly contraindicated during pregnancy due to theoretical teratogenicity and require a 1-month (28-day) interval of reliable contraception following administration; inactivated influenza, COVID-19, and hepatitis B vaccines are safe, and ACOG's 2026 schedule recommends influenza and COVID-19 vaccination in pregnancy.
Preconception Care: Principles, Goals & Timing
Preconception care is the provision of biomedical, behavioral, and social health interventions to individuals of reproductive potential before conception occurs. The overarching goal is to improve maternal, fetal, and neonatal outcomes by optimizing health status and mitigating modifiable risks prior to pregnancy.
Clinical Timing & The "One Key Question"
National guidelines from the American College of Obstetricians and Gynecologists (ACOG) and the Centers for Disease Control and Prevention (CDC) emphasize that preconception care must not be reserved for designated "pre-pregnancy visits." Instead, clinicians should integrate preconception assessment into every routine primary care and well-woman encounter across the reproductive lifespan. Routine screening begins with "The One Key Question": "Would you like to become pregnant in the next year?"
- If yes: Initiate formal preconception counseling, chronic illness optimization, medication reconciliation, and genetic screening.
- If no: Provide evidence-based contraceptive counseling, STI screening, and reproductive life planning.
- If ambivalent / unsure: Optimize general health and nutrition while establishing an appropriate family planning bridge.
The Critical Window of Organogenesis
The imperative for proactive preconception counseling is dictated by human embryology:
- Weeks 1–2 Post-Conception (Menstrual Weeks 3–4): The "All-or-None" period. Teratogenic insults or toxic exposures during pre-implantation and early blastocyst development either kill the embryo (resulting in early spontaneous resorption) or leave surviving totipotent cells capable of complete compensation and normal embryogenesis without structural malformations.
- Weeks 3–8 Post-Conception (Menstrual Weeks 5–10): The critical period of organogenesis. During this window, all major internal and external organ systems (central nervous system, heart, limbs, eyes, palate, and urogenital tract) undergo primary structural differentiation. Major structural teratogenesis occurs during this vulnerable phase. Because neural tube closure completes by day 28 post-conception (day 42 from LMP)—often before a patient realizes menses are late—preconception intervention is mandatory.
- Week 9 Post-Conception to Term (Fetal Period): Tissues undergo functional maturation and histogenesis. Teratogen exposure during this phase typically causes functional deficits, central nervous system behavioral derangements, or fetal growth restriction rather than gross anatomical agenesis.
Chronic Disease Optimization Prior to Conception
Maternal chronic medical conditions must be stabilized and reassessed prior to conception to minimize maternal morbidity and fetal teratogenicity.
| Medical Condition | Preconception Clinical Target | Pharmacotherapy Adjustments & High-Yield Pearls |
|---|---|---|
| Pregestational Diabetes (Type 1 or Type 2) | • Glycemic Target: A1C <6.5% (or <6.0% without hypoglycemia). • Fasting glucose 70–95 mg/dL; 1-hr postprandial ≤140 mg/dL. • Baseline microvascular screen: dilated eye exam, serum creatinine, urine albumin-to-creatinine ratio, baseline ECG. | • Uncontrolled maternal hyperglycemia during organogenesis causes cardiac malformations (transposition of great arteries, VSD, coarctation), neural tube defects (anencephaly, spina bifida), and caudal regression syndrome (sacral agenesis), which is pathognomonic for diabetic embryopathy. • Transition oral hypoglycemic agents to insulin if needed. • Start folic acid of at least 0.4 mg daily (some clinicians use higher doses; evidence for 4 mg in diabetes is limited). |
| Chronic Hypertension | • Target BP: 120–130 / 80–85 mmHg. • Baseline organ damage assessment: serum creatinine, BUN, electrolytes, urinalysis, ECG. | • Strictly Contraindicated: ACE inhibitors, ARBs, and direct renin inhibitors cause RAAS fetopathy (second/third trimester renal tubular dysgenesis, oligohydramnios sequence, pulmonary hypoplasia, neonatal renal failure, calvarial hypoplasia). • Mineralocorticoid Receptor Antagonists: Spironolactone causes feminization of male fetuses. • First-Line Safe Agents: Oral labetalol, extended-release nifedipine, or methyldopa. |
| Thyroid Disease (Hypothyroidism) | • Preconception TSH: <2.5 mIU/L. • Uncontrolled hypothyroidism increases risks of spontaneous abortion, preeclampsia, placental abruption, low birth weight, and neurodevelopmental deficits. | • Upon confirmation of pregnancy, maternal estrogen stimulates a rapid 2- to 3-fold elevation in thyroxine-binding globulin (TBG). • Patients on levothyroxine must increase their daily dose by 20% to 30% (typically taking 2 additional tablets per week, or 9 doses per week instead of 7) immediately upon a positive pregnancy test. • Monitor TSH every 4 weeks through the first half of pregnancy. |
| Epilepsy / Seizure Disorders | • Complete seizure freedom for ≥6 to 12 months prior to conception. • Maternal convulsions cause severe fetal hypoxemia, bradycardia, and trauma. | • Optimize to monotherapy at the lowest effective dose. • Avoid Valproate (valproic acid / divalproex): Highest teratogenic potential (10–15% malformation risk: 1–2% neural tube defects, facial clefts, craniosynostosis, long-term reduced verbal IQ and autism spectrum disorders). • Preferred alternatives: Lamotrigine or levetiracetam. • Prescribe folic acid of at least 0.4 mg daily before and during pregnancy (AAN/AES/SMFM 2024); higher doses are common but not proven superior. |
Important
Renin-angiotensin-aldosterone system (RAAS) inhibitors (ACE inhibitors and ARBs) are strictly contraindicated in pregnancy. They induce severe second- and third-trimester fetopathy, including renal tubular dysgenesis, severe oligohydramnios leading to Potter sequence (pulmonary hypoplasia and limb contractures), neonatal anuria, and skull ossification defects (hypocalvaria). Any patient of childbearing potential taking an ACE inhibitor or ARB should be transitioned to labetalol or extended-release nifedipine prior to attempting conception.
Evidence-Based Folic Acid Supplementation Protocols
Folic acid supplementation is the single most effective public health and clinical intervention for the primary prevention of neural tube defects (NTDs), which include anencephaly, encephalocele, and spina bifida (myelomeningocele). Because the neural folds fuse to close the neural tube between day 22 and day 28 post-conception (menstrual weeks 5 to 6), supplementation must be established prior to conception.
Risk-Stratified Dosing Guidelines
- Average-Risk Individuals:
- Dose: 400–800 mcg (0.4–0.8 mg) daily orally (USPSTF 2023).
- Timing: Initiated at least 1 month prior to conception and continued daily throughout the first trimester (and continued as part of routine prenatal multivitamin care through pregnancy and lactation).
- Candidates: All individuals of childbearing potential with no personal or familial risk factors for NTDs.
- High-Risk Individuals:
- Dose: 4,000 mcg (4.0 mg) daily orally.
- Timing: Initiated at least 1 to 3 months prior to conception and continued through at least the first 12 weeks of gestation, after which the dose may be reduced to standard prenatal multivitamin dosing (400 to 800 mcg daily).
- Candidates: A prior NTD-affected pregnancy is the indication ACOG and CDC endorse; for the other groups, practice varies and the evidence for 4 mg is weaker.
- Personal history of a previous pregnancy or infant affected by an open neural tube defect.
- Personal history of an NTD in either biologic parent.
- Maternal pregestational diabetes mellitus (Type 1 or Type 2).
- Maternal use of folate-antagonizing anti-seizure medications (e.g., carbamazepine, valproate, phenobarbital, topiramate).
- Malabsorptive gastrointestinal conditions (e.g., celiac disease, active Crohn's disease, prior Roux-en-Y gastric bypass).
Tip
Over-the-counter prenatal multivitamins typically contain 400 to 800 mcg of folic acid. Clinicians must prescribe dedicated folic acid (1 mg tablets, 4 tablets daily) to achieve the 4,000 mcg (4.0 mg) high-risk target, rather than advising patients to take multiple OTC multivitamins, which would result in toxic hypervitaminosis A (retinol teratogenicity).
Genetic Carrier Screening: Panels & Strategies
Carrier screening identifies individuals and couples at risk of passing autosomal recessive or X-linked genetic disorders to their offspring. ACOG and the American College of Medical Genetics and Genomics (ACMG) recommend that carrier screening be offered to all individuals considering pregnancy or during early pregnancy.
Universal Carrier Screening (Offered to All Patients)
- Cystic Fibrosis (CF): Autosomal recessive mutation in the CFTR gene on chromosome 7. Screening is universally offered regardless of race or ethnicity.
- Spinal Muscular Atrophy (SMA): Autosomal recessive neurodegenerative disorder caused by SMN1 gene deletions/mutations on chromosome 5q. Screening is universally offered to all individuals.
- Hemoglobinopathies: Screening begins with a Complete Blood Count (CBC) with red blood cell indices. If the mean corpuscular volume (MCV) is <80 fL in the absence of iron deficiency, or if the patient is of high-risk ethnicity (African, Mediterranean, Middle Eastern, Southeast Asian), perform hemoglobin electrophoresis (or HPLC) to screen for sickle cell trait/disease, beta-thalassemia minor/major, and hemoglobin C/E variants. Molecular DNA testing is required to detect alpha-thalassemia deletions.
Ancestry-Based & Expanded Carrier Screening
- Ashkenazi Jewish Carrier Panel: Individuals of Eastern European Jewish descent carry heightened carrier frequencies for lethal or severe neurodegenerative conditions: Tay-Sachs disease (hexosaminidase A deficiency), Canavan disease, familial dysautonomia, Gaucher disease, Niemann-Pick disease type A, Bloom syndrome, Fanconi anemia group C, and mucolipidosis IV.
- Expanded Carrier Screening (ECS): Pan-ethnic panels screening for 100 to 500+ recessive and X-linked genetic conditions simultaneously. Pre-test counseling must address the likelihood of identifying positive carrier status and the reality of residual risk (a negative test significantly reduces, but does not completely eliminate, the possibility of being a carrier).
- Partner Testing Rule: If a patient tests positive as a carrier for an autosomal recessive condition, the reproductive partner (sperm source) should be offered testing promptly. If both parents are confirmed carriers, each pregnancy carries a 25% (1 in 4) risk of being affected, warranting referral to a certified genetic counselor for pre-implantation genetic testing (PGT) or invasive prenatal diagnostic testing (CVS or amniocentesis).
Infectious Disease Immunity & Preconception Immunizations
Assessing infectious disease titers preconception allows clinicians to identify non-immune individuals and vaccinate them prior to pregnancy, avoiding catastrophic congenital infection syndromes.
Evaluation of Maternal Immunity
- Rubella IgG Titer: Evaluates immunity against rubella virus. Congenital Rubella Syndrome (CRS) causes sensorineural deafness, cataracts, microphthalmia, congenital heart disease (patent ductus arteriosus, pulmonary artery stenosis), and hepatosplenomegaly.
- Varicella IgG Titer: Evaluates immunity against varicella-zoster virus. Congenital Varicella Syndrome causes cicatricial skin scarring, limb hypoplasia, microcephaly, chorioretinitis, and cortical atrophy.
Preconception Vaccine Safety Matrix
| Vaccine Class | Specific Vaccines | Clinical Recommendation & Contraception Interval |
|---|---|---|
| Live Attenuated Vaccines | • MMR (Measles, Mumps, Rubella) • Varicella (Varivax) • Live Attenuated Influenza (Nasal Spray) | • Strictly Contraindicated during pregnancy due to theoretical risk of viral replication and transplacental transmission. • Administer to non-immune patients preconception. • Advise patient to avoid pregnancy and maintain reliable contraception for at least 1 month (28 days) following live vaccine administration. |
| Inactivated / Recombinant Vaccines | • Inactivated Influenza (Injection) • COVID-19 (mRNA) • Hepatitis B (Recombinant) • Tdap (Tetanus, Diphtheria, Pertussis) | • Safe before or during pregnancy. • ACOG's 2026 Maternal Immunization Schedule recommends inactivated influenza and COVID-19 vaccination in any trimester (CDC shifted COVID-19 vaccination to individual decision-making in 2025). • Tdap is given in every pregnancy at 27–36 weeks. |
Note
If an inadvertently administered live vaccine occurs within the 1-month window or during early pregnancy, the patient should be counseled that registry data show the actual risk of congenital rubella or varicella syndrome is virtually zero; inadvertent vaccination is NOT an indication for termination of pregnancy.
Major Teratogens & Clinical Manifestations
A teratogen is any environmental exposure, chemical substance, drug, infection, or maternal metabolic state capable of inducing permanent structural or functional defects in the developing embryo or fetus.
| Teratogenic Agent | Clinical Window of Vulnerability | Characteristic Malformations / Fetopathy Syndrome |
|---|---|---|
| Isotretinoin (Accutane / Oral Retinoids) | Weeks 3–8 post-conception (first trimester) | • Retinoic Acid Embryopathy: Craniofacial dysmorphism (microtia, anotia, low-set ears, cleft palate), conotruncal cardiovascular defects (transposition, tetralogy of Fallot), thymic aplasia, microcephaly, hydrocephalus. • Strictly controlled via the iPLEDGE program: 2 negative pregnancy tests prior to starting; 2 concurrent forms of contraception; discontinue ≥1 month prior to conception. |
| Warfarin (Coumadin) | Weeks 6–9 post-conception (first trimester) | • Fetal Warfarin Syndrome: Nasal hypoplasia with depressed nasal bridge, stippled epiphyses (chondrodysplasia punctata), optic atrophy, microcephaly, developmental delay. • Later trimester exposure causes fetal intracranial hemorrhage and microcephaly. • Transition to therapeutic low-molecular-weight heparin (LMWH) prior to conception. |
| Methotrexate (Folate Antagonist) | First trimester | • Aminopterin / Methotrexate Syndrome: Cranial dysostosis (cloverleaf skull, wide fontanelles), severe micrognathia, limb reduction abnormalities, growth restriction, and spontaneous abortion. • Discontinue at least 3 months prior to planned conception. |
| ACE Inhibitors & ARBs (Lisinopril, Losartan) | Second and third trimesters (and first trimester cardiac risk) | • RAAS Fetopathy: Fetal renal tubular dysgenesis, renal failure, severe oligohydramnios resulting in Potter sequence (pulmonary hypoplasia, limb contractures, facial flattening), neonatal anuria, and calvarial hypoplasia (defective skull bone ossification). |
| Lithium | Weeks 4–8 post-conception (first trimester) | • Ebstein Anomaly: Apical displacement of the tricuspid valve leaflets into the right ventricle, tricuspid regurgitation, severe right atrial enlargement, and accessory conduction pathways (Wolff-Parkinson-White). |
| Alcohol (Ethanol) | Entire gestation (dose-dependent, no safe threshold) | • Fetal Alcohol Spectrum Disorder (FASD): Leading preventable cause of intellectual disability in the Western world. • Facial Triad: Smooth philtrum, thin vermilion border of the upper lip, and short palpebral fissures. • Microcephaly, pre- and post-natal growth restriction, structural cardiac and skeletal defects, permanent executive cognitive and behavioral dysfunction. |
A 29-year-old female presents to the clinic for a well-woman examination. During the encounter, she states that she and her husband plan to discontinue barrier contraception and attempt pregnancy within the next 2 months. Her medical history is significant for primary chronic hypertension diagnosed 3 years ago, which is currently well managed on lisinopril 10 mg daily (blood pressure today is 122/76 mmHg). Physical examination and baseline renal laboratories are normal. What is the most appropriate evidence-based pharmacotherapeutic management plan regarding her antihypertensive medication?
Instruct the patient to continue lisinopril until she achieves a positive home pregnancy test, then discontinue it immediately.
Discontinue lisinopril now and transition her to oral labetalol or extended-release nifedipine, while initiating folic acid 400 mcg daily.
Switch lisinopril to an angiotensin II receptor blocker (ARB) such as losartan, which has a superior first-trimester safety profile.
Discontinue lisinopril and initiate spironolactone 50 mg daily, as mineralocorticoid receptor antagonists are preferred in early gestation.
A 27-year-old female presents for preconception counseling. Her obstetric history is notable for a previous pregnancy delivered 2 years ago that was complicated by fetal anencephaly, resulting in a stillbirth at 20 weeks of gestation. She takes no medications, has no other medical conditions, and is eager to conceive again. According to national clinical guidelines, what folic acid supplementation regimen should the WHNP prescribe for this patient?
Oral folic acid 400 mcg daily starting immediately upon confirmation of a positive pregnancy test and continuing through term.
Oral folic acid 800 mcg daily starting 2 weeks prior to conception and continuing through delivery.
Oral folic acid 1,000 mcg daily starting in the second trimester after organogenesis is complete.
Oral folic acid 4 mg (4,000 mcg) daily from at least 1–3 months before conception through 12 weeks of gestation.
A 31-year-old female with primary hypothyroidism well controlled on oral levothyroxine 75 mcg daily (preconception TSH 1.8 mIU/L) presents to the clinic with a positive home pregnancy test at 5 weeks of gestation. She reports mild breast tenderness and fatigue but is otherwise asymptomatic. What is the most appropriate next step in the clinical management of her thyroid medication?
Instruct the patient to immediately increase her daily levothyroxine dose by approximately 20% to 30% and schedule a repeat serum TSH in 4 weeks.
Maintain her current levothyroxine dosage of 75 mcg daily and defer any dose titration until her scheduled 20-week anatomy ultrasound.
Discontinue levothyroxine immediately because exogenous levothyroxine crosses the placenta and suppresses fetal thyroid development.
Decrease her levothyroxine dose by 25% to account for reduced renal clearance and increased circulating blood volume in early pregnancy.
Sections you finish are checked off in the contents.